PUBLISHER: DelveInsight | PRODUCT CODE: 1462319
PUBLISHER: DelveInsight | PRODUCT CODE: 1462319
"VS-6766 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about VS-6766 for ovarian cancer in the seven major markets. A detailed picture of the VS-6766 for ovarian cancer in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the VS-6766 for ovarian cancer. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VS-6766 market forecast analysis for ovarian cancer in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ovarian cancer.
VS-6766, developed by Verastem Oncology, is an RAF/MEK clamp that induces inactive complexes of MEK with ARAF, BRAF, and CRAF, potentially creating a more complete and durable antitumor response through maximal RAS pathway inhibition. VS-6766 blocks both RAF and MEK in a single molecule, suggesting it may help overcome resistance and ultimately block tumor growth and proliferation. By inhibiting RAF phosphorylation of MEK, VS-6766 has the advantage of not inducing pMEK, and by inhibiting ERK signaling more completely, preliminary research indicates VS-6766 may confer enhanced therapeutic activity. When used alone, preliminary data show that VS-6766 demonstrates across RAS pathway mutations in refractory gynecologic cancers.
VS-6766 offers a novel intermittent dosing schedule and convenient oral regimen with the possibility of better tolerability than currently available MEK-only inhibitors, which makes VS-6766 an optimal partner for combination therapy with agents from multiple target classes that may deliver better patient outcomes where they are needed most.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
VS-6766 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of VS-6766 for ovarian cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.
The report provides the clinical trials information of VS-6766 for ovarian cancer covering trial interventions, trial conditions, trial status, start and completion dates.